A major barrier for
cancer immunotherapy is the presence of suppressive cell populations in patients with
cancer, such as myeloid-derived suppressor cells (MDSC) and tumor-associated macrophages (TAM), which contribute to the immunosuppressive microenvironment that promotes
tumor growth and
metastasis.
Tasquinimod is a novel
antitumor agent that is currently at an advanced stage of clinical development for treatment of
castration-resistant
prostate cancer. A target of
tasquinimod is the inflammatory
protein S100A9, which has been demonstrated to affect the accumulation and function of
tumor-suppressive myeloid cells. Here, we report that
tasquinimod provided a significant enhancement to the antitumor effects of two different immunotherapeutics in mouse models of
cancer: a
tumor vaccine (SurVaxM) for
prostate cancer and a
tumor-targeted
superantigen (TTS) for
melanoma. In the combination strategies,
tasquinimod inhibited distinct MDSC populations and TAMs of the M2-polarized phenotype (CD206(+)). CD11b(+) myeloid cells isolated from
tumors of treated mice expressed lower levels of arginase-1 and higher levels of
inducible nitric oxide synthase (iNOS), and were less immunosuppressive ex vivo, which translated into a significantly reduced
tumor-promoting capacity in vivo when these cells were coinjected with
tumor cells.
Tumor-specific CD8(+) T cells were increased markedly in the circulation and in
tumors. Furthermore, T-cell effector functions, including cell-mediated cytotoxicity and IFNγ production, were potentiated. Taken together, these data suggest that pharmacologic targeting of suppressive myeloid cells by
tasquinimod induces therapeutic benefit and provide the rationale for clinical testing of
tasquinimod in combination with
cancer immunotherapies.